Increasing the rate of heating: A potential therapeutic approach for achieving synergistic tumour killing in combined hyperthermia and chemotherapy

International Journal of Hyperthermia

Volumn 29, Issue 2, 2013, Pages 145-155

  Tang, Yuan ^a   McGoron, Anthony J ^b  

^a Temple University   (United States)

^b The Department of Electrical and Computer Engineering   (United States)

Author keywords

Apoptosis; Doxorubicin; Hyperthermia; Indocyanine green; Multi drug resistance; Necrosis; Thermotolerance

Indexed keywords

DOXORUBICIN; HEAT SHOCK PROTEIN 70; INDOCYANINE GREEN; MULTIDRUG RESISTANCE PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CULTURE; CELL DEATH; CELL MEMBRANE; CELL NUCLEUS; CONTROLLED STUDY; HEAT TOLERANCE; HEATING; HUMAN; HUMAN CELL; HYPERTHERMIC THERAPY; INFRARED RADIATION; MEMBRANE DAMAGE; PROTEIN EXPRESSION; UTERUS CANCER;

EID: 84874047958     PISSN: 02656736     EISSN: 14645157     Source Type: Journal    
DOI: 10.3109/02656736.2012.760757     Document Type: Article

References (52)

1. Mostafa EM, Ganguli S, Faintuch S, Mertyna P, Goldberg SN. Optimal strategies for combining transcatheter arterial chemoembolization and radiofrequency ablation in rabbit VX2 hepatic tumors. J Vasc Intervent Radiol 2008;19:1740-1748.
2. Taeger G, Grabellus F, Podleska LE, Mèuller S, Ruchholtz S. Effectiveness of regional chemotherapy with TNF-alpha/melphalan in advanced soft tissue sarcoma of the extremities. Int J Hyperthermia 2008;24:193-203.
3. Ko SH, Ueno T, Yoshimoto Y, Yoo JS, Abdel-Wahab OI, Abdel-Wahab Z, et al. Optimizing a novel regional chemotherapeutic agent against melanoma: Hyperthermia-induced enhancement of temozolomide cytotoxicity. Clin Cancer Res 2006;12:289-297.
4. Kampinga HH. Cell biological effects of hyperthermia alone or combined with radiation or drugs: A short introduction to newcomers in the field. Int J Hyperthermia 2006;22:191-196.
5. Gottesman MM. How cancer cells evade chemotherapy: Sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1993;53:747-754.
6. Riordan JR, Deuchars K, Kartner N, Alon N, Trent J, Ling V. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature 1985;316:817-819.
7. Liu Y, Cho CW, Yan X, Henthorn TK, Lillehei KO, Cobb WN, et al. Ultrasound-induced hyperthermia increases cellular uptake and cytotoxicity of P-glycoprotein substrates in multi-drug resistant cells. Pharm Res 2001;18:1255-1261.
8. Huang CH, Li YP, Cao PG, Xie ZX, Qin ZQ. Synergistic effect of hyperthermia and neferine on reverse multidrug resistance in adriamycin-resistant SGC7901/ADM gastric cancer cells. J Huazhong Univ Sci Tech Med Sci 2011;31:488-496.
9. Bidwell GL, Davis AN, Fokt I, Priebe W, Raucher D. A thermally targeted elastin-like polypeptide-doxorubicin conjugate overcomes drug resistance. Investig New Drug 2007;25:313-326.
10. Moriyama-Gonda N, Igawa M, Shiina H, Wada Y. Heatinduced membrane damage combined with adriamycin on prostate carcinoma PC-3 cells: Correlation of cytotoxicity, permeability and P-glycoprotein or metallothionein expression. Br J Urology 1998;82:552-559.
11. Pietzner K, Schmuck RB, Fotopoulou C, Gellermann J, Ismaeel F, Cho CH, et al. Long term combination treatment with bevacizumab, pegylated liposomal doxorubicin and regional abdominal hyperthermia in platinum refractory ovarian cancer: A case report and review of the literature. Anticancer Res 2011;31:2675-2677.
12. Feyerabend S, Stevanovic S, Gouttefangeas C, Wernet D, Hennenlotter J, Bedke J, et al. Novel multi-peptide vaccination in HLA-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate 2009;69:917-927.
13. Hildebrandt B, Wust P, Ahlers O, Dieing A, Sreenivasa G, Kerner T, et al. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol 2002;43:33-56.
14. Christophi C, Winkworth A, Muralihdaran V, Evans P. The treatment of malignancy by hyperthermia. Surg Oncol 1998;7:83-90.
15. Tang Y, McGoron AJ. Combined effects of laser-ICG photothermotherapy and doxorubicin chemotherapy on ovarian cancer cells. J Photochem Photobiol B Biol 2009;97:138-144.
16. Li GC, Mivechi NF, Weitzel G. Heat shock proteins, thermotolerance, and their relevance to clinical hyperthermia. Int J Hyperthermia 1995;11:459-488.
17. Anderson RL, Herman TS, van Kersen I, Hahn GM. Thermotolerance and heat shock protein induction by slow rates of heating. Int J Radiat Oncol Biol Phys 1988;15:717-725.
18. Herman TS, Sweets CC, White DM, Gerner EW. Effect of heating on lethality due to hyperthermia and selected chemotherapeutic drugs. J Natl Cancer Inst 1982;68:487-491.
19. Hahn GM, Strande DP. Cytotoxic effects of hyperthermia and adriamycin on Chinese hamster cells. J Natl Cancer Inst 1976;57:1063-1067.
20. Ponce AM, Vujaskovic Z, Yuan F, Needham D, Dewhirst MW. Hyperthermia mediated liposomal drug delivery. Int J Hyperthermia 2006;22:205-213.
21. Mackay JA, Chilkoti A. Temperature sensitive peptides: Engineering hyperthermia-directed therapeutics. Int J Hyperthermia 2008;24:483-495.
22. Yarmolenko PS, Zhao Y, Landon C, Spasojevic I, Yuan F, Needham D, et al. Comparative effects of thermosensitive doxorubicin-containing liposomes and hyperthermia in human and murine tumours. Int J Hyperthermia 2010;26:485-498.
23. Kampinga HH. Hyperthermia, thermotolerance and topoisomerase II inhibitors. Br J Cancer 1995;72:333-338.
24. Ciocca DR, Oesterreich S, Chamness GC, McGuire WL, Fuqua SA. Biological and clinical implications of heat shock protein 27 000 (Hsp27): A review. J Natl Cancer Institute 1993;85:1558-1570.
25. Oh HJ, Chen X, Subjeck JR. Hsp110 protects heat-denatured proteins and confers cellular thermoresistance. J Biol Chem 1997;272:31636-31640.
26. Fisher B, Kraft P, Hahn GM, Anderson RL. Thermotolerance in the absence of induced heat shock proteins in a murine lymphoma. Cancer Res 1992;52:2854-2861.
27. Sapareto SA, Dewey WC. Thermal dose determination in cancer therapy. Int J Radiat Oncol Biol Phys 1984;10:787-800.
28. Rezai KA, Farrokh-Siar L, Ernest JT, van Seventer GA. Indocyanine green induces apoptosis in human retinal pigment epithelial cells. Am J Ophthalmol 2004;137:931-933.
29. Wolfe JD, Csaky KG. Indocyanine green enhanced retinal vessel laser closure in rats: Histologic and immunohistochemical observations. Exp Eye Res 2004;79:631-638.
30. Flanagan SW, Ryan AJ, Gisolfi CV, Moseley PL. Tissuespecific Hsp70 response in animals undergoing heat-stress. Am J Physiol-Regulat Integr Compar Physiol 1995;268:R28-R32.
31. Burns CP, Lambert BJ, Haugstad BN, Guffy MM. Influence of rate of heating on thermosensitivity of L1210 leukemia -membrane-lipids and Mr 70 000 heat-shock protein. Cancer Res 1986;46:1882-1887.
32. Herman TS, Gerner EW, Magun BE, Stickney D, Sweets CC, White DM. Rate of heating as a determinant of hyperthermic cyto-toxicity. Cancer Res 1981;41:3519-3523.
33. Amorim FT, Yamada PM, Robergs RA, Schneider SM, Moseley PL. The effect of the rate of heat storage on serum heat shock protein 72 in humans. Eur J Appl Physiol 2008;104:965-972.
34. De Maio A. Heat shock proteins: Facts, thoughts, and dreams. Shock 1999;11:1-12.
35. Donaldson SS, Gordon LF, Hahn GM. Protective effect of hyperthermia against the cytotoxicity of actinomycin D on Chinese hamster cells. Cancer Treat Rep 1978;62:1489-1495.
36. Wallner K, Li GC. Adriamycin resistance, heat resistance and radiation response in Chinese hamster fibroblasts. Int J Radiat Oncol Biol Phys 1986;12:829-833.
37. Pirity M, Hever-Szabo A, Venetianer A. Overexpression of Pglycoprotein in heat-and/or drug-resistant hepatoma variants. Cytotechnol 1996;19:207-214.
38. Tchénio T, Havard M, Martinez LA, Dautry F. Heat shockindependent induction of multidrug resistance by heat shock factor 1. Mol Cell Biol 2006;26:580-591.
39. Thorburn A, Frankel AE. Apoptosis and anthracycline cardiotoxicity. Mol Cancer Therapeut 2006;5:197-199.
40. Ling YH, Priebe W, Perez-Soler R. Apoptosis induced by anthracycline antibiotics in P388 parent and multidrugresistant cells. Cancer Res 1993;53:1845-1852.
41. Skladanowski A, Konopa J. Adriamycin and daunomycin induce programmed cell death (apoptosis) in tumour cells. Biochem Pharmacol 1993;46:375-382.
42. Zaleskis G, Berleth E, Verstovsek S, Ehrke MJ, Mihich E. Doxorubicin-induced DNA degradation in murine thymocytes. Mol Pharmacol 1994;46:901-908.
43. Bose R, Verheij M, Haimovitz-Friedman A, Scotto K, Fuks Z, Kolesnick R. Ceramide synthase mediates daunorubicininduced apoptosis: An alternative mechanism for generating death signals. Cell 1995;82:405-414.
44. Jaffrâezou JP, Levade T, Bettaèieb A, Andrieu N, Bezombes C, Maestre N, et al. Daunorubicin-induced apoptosis: Triggering of ceramide generation through sphingomyelin hydrolysis. EMBO J 1996;15:2417-2424.
45. Angelini A, Iezzi M, Di Febbo C, Di Ilio C, Cuccurullo F, Porreca E. Reversal of P-glycoprotein-mediated multidrug resistance in human sarcoma MES-SA/Dx-5 cells by nonsteroidal anti-inflammatory drugs. Oncol Rep 2008;20:731-735.
46. Samali A, Holmberg CI, Sistonen L, Orrenius S. Thermotolerance and cell death are distinct cellular responses to stress: Dependence on heat shock proteins. FEBS Lett 1999;461:306-310.
47. Milleron RS, Bratton SB. 'Heated' debates in apoptosis. Cell Mol Life Sci 2007;64:2329-2333.
48. Bettaieb A, Averill-Bates DA. Thermotolerance induced at a mild temperature of 40°C protects cells against heat shockinduced apoptosis. J Cell Physiol 2005;205:47-57.
49. Weiss RB. The anthracyclines: Will we ever find a better doxorubicin? Semin Oncol 1992;19:670-686.
50. Singal PK, Li T, Kumar D, Danelisen I, Iliskovic N. Adriamycin-induced heart failure: Mechanism and modulation. Mol Cell Biochem 2000;207:77-86.
51. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56:185-229.
52. Rose PG. Pegylated liposomal doxorubicin: Optimizing the dosing schedule in ovarian cancer. Oncologist 2005;10:205-214.